Hepatitis C virus (HCV) infection causes 500,000 deaths annually, associated with end-stage 42 liver diseases. Investigations of the HCV life cycle widened the knowledge in virology, and 43 here we discovered that two piperazinylbenzenesulfonamides inhibit HCV entry into liver 44 cells. The entry process of HCV into host cells is a complex process, not fully understood, but 45 characterized by multiple spatially and temporally regulated steps involving several known 46 host factors. Through a high-content virus-infection screening analysis with a library of 1,120 47 of the serotonin receptor 6, but instead through modulation of PKA activity in a 5-HT6 66 independent manner, as proven by the lack of 5-HT6 in liver. We thus highlighted the 67 involvement of PKA pathway in modulating HCV post-binding step entry and in the 68 recycling of the tight junction protein claudin-1 (CLDN1) towards the cell surface. Our work 69 underscores once more the complexity of HCV entry steps and suggests a role for PKA 70 pathway as regulator of CLDN1 recycling, having an impact on both cell biology and 71 virology. 72 73
biologically active chemical compounds, we identified SB258585, an antagonist of the 48 serotonin receptor 6 (5-HT6), as a new inhibitor of HCV entry in liver-derived cell lines, as 49 well as in primary hepatocytes. A functional characterization suggested a role for this 50 compound, as well as for the compound SB399885 sharing a similar structure, as inhibitors of 51 a late HCV entry step, modulating the localization of the co-receptor tight junction protein 52 claudin 1 (CLDN1), in a 5-HT6 independent manner. Both chemical compounds induced an 53 intracellular accumulation of CLDN1, reflecting export impairment. This regulation 54 correlated with the modulation of protein kinase A (PKA) activity. The PKA inhibitor H89 55 fully reproduced these phenotypes. Furthermore, PKA activation resulted in increased 56 CLDN1 accumulation at the cell surface. Interestingly, increase of CLDN1 recycling did not 57 correlate with an increased interaction with CD81 or HCV entry. These findings reinforce the 58 hypothesis of a common pathway shared by several viruses, which involves G-protein 59 coupled receptor -dependent signaling in late steps of viral entry. 60
IMPORTANCE 61
The HCV entry process is highly complex and important details of this structured event are 62 poorly understood. By screening a library of biologically active chemical compounds, we 63 identified two piperazinylbenzenesulfonamides as inhibitors of HCV entry. The mechanism 64 of inhibition was not through previously described activity of these inhibitors as antagonists 65
INTRODUCTION 74
Virus entry into specific host cells is a tightly regulated multistep process. Among 75 known viruses, the liver pathogen hepatitis C virus (HCV), which causes 500,000 deaths 76
annually, has probably one of the most complex multistep entry processes involving a 77 growing number of cellular entry factors (1). Furthermore, the regulation of trafficking of 78 these proteins provides an additional level of complexity. Although the involvement of a large 79 number of host factors has been demonstrated in HCV entry, several gaps remain in our 80 comprehension of this process. Further functional studies are therefore needed to better 81 understand the regulation of the early steps of the HCV life cycle. 82
After binding to attachment factors such as heparan sulfate proteoglycans and the low 83 density lipoprotein (LDL) receptor, HCV particles specifically bind to the entry receptors 84 scavenger receptor BI (SRB1) and CD81 tetraspanin (2). HCV binding to CD81 induces a 85 diffusion of this virion-tetraspanin complex on the plasma membrane, towards the sites of 86 viral internalization (3). Only a specific fraction of CD81, located outside of tetraspanin-87 enriched areas, is involved in HCV entry (4) through its interaction with the tight junction 88 protein claudin 1 (CLDN1) (5-7). Importantly, CD81-CLDN1 interaction is a major event 89
driving HCV endocytosis (8). Among other identified host factors involved in HCV entry (2), 90 occludin (OCLN), another tight-junction protein, also plays a major role in a late step of HCV 91 entry through an unknown mechanism (9). Together, these observations indicate that tight 92 junction proteins play a central role in HCV entry. However, the regulation of these proteins 93 in the liver remains poorly understood and little information is available on CLDN1 94 trafficking and its interplay with CD81 and OCLN both in infected and non-infected cells. 95
In this study, we implemented a high-content screening (HCS) approach using a 96 library of chemical compounds to search for new regulators of HCV entry. We identified 97 serotonin receptor 6 (5-HT6) antagonists SB258585 and SB399885 as inhibitors of a late step 98 of HCV entry. More specifically, we showed a reduction of PKA activation upon treatment, 99 in a 5-HT6-independent manner. We confirmed the involvement of PKA pathway in HCV 100 entry and a role of its activation in CLDN1 export. Taken together, these data identify new 101 inhibitors of HCV post-binding step and provide new findings in regulation of CLDN1 102 transport and function. This work highlights once more the complexity of the HCV entry 103 process proving that the presence of CLDN1 at the cell surface is not sufficient to mediate its 104 interaction with CD81. This confirms the importance of the membrane environment and the 105 need of the synergistic action of several receptors in HCV entry. To identify new cellular factors involved in the early steps of the HCV infectious 111 cycle, we performed a HCS using a library of 1,120 biologically active chemical compounds. 112
The screen was repeated using three different concentrations (1 µM, 10 µM and 20 µM) in 113
Huh-7 cells infected with cell culture derived HCV (HCVcc) strain JFH1 (genotype 2a) (10, 114 11). A re-infection experiment was performed as an additional filter to eliminate false-115 positive compounds (Supplemantal dataset S1). Compounds reducing the infection by at least 116 45% compared to the average of DMSO wells affecting cell viability for less than 35% were 117 considered as positive hits ( Fig. 1A-C ). Finally, we only retained compounds confirmed in the 118 re-infection experiment and inhibiting HCV infection for at least two of the three tested 119 concentrations ( Fig. 1D and Table 1 ). According to these criteria, 20 compounds were 120 selected. Nine of them had been previously described as having an inhibitory effect on HCV 121 or targeting cellular pathways identified as important for HCV infection, thus validating our 122 screen (12-16). Among the 11 remaining hits, we identified 5 compounds targeting serotonin 123
(5-HT) receptors or transporters. Serotonin receptors constitute a class of 16 human receptors, 124 none of which have ever been identified as host factor involved in the HCV infectious cycle. 125
To identify the 5-HT receptor(s) playing a role in HCV infection, we searched the Tocriscreen 126
Total library for all the compounds targeting in a more or less specific manner each of these 127 receptors, in accordance with data available on the following databases: 128 http://www.guidetopharmacology.org/ and http://stitch.embl. de (17) . Interestingly, with only 129 one exception, all the compounds targeting the serotonin receptor 6 (5-HT6) showed a dose-130 response inhibitory effect on HCV JFH1 infection ( Fig. 1E) , in contrast to the compounds 131 targeting other 5-HT receptors where, for most of them, only the highest concentration 132 showed an inhibitory activity. Among the inhibitors of 5-HT6, SB258585 was identified as a 133 hit according to the criteria of lack of cell toxicity and inhibition of infection chosen in the 134 screen ( Fig. 1F and Table 1) . 135 136 SB258585 inhibits HCV infection, down-regulating PKA activity independently of 5-137
HT6 receptor. 138
In order to confirm the inhibitory effect of 5-HT6 antagonist SB258585 on HCV viral 139 cycle, kinetics of JFH1 infection were performed in the presence of this compound. The 140 maximum inhibitory effect of SB258585 was observed when the chemical compound was 141 added during the inoculation of the virus ( Fig. 2A ), suggesting an effect on virus entry. As 142 shown in Fig. 2B , the inhibition was not due to drug toxicity. 143 5-HT6 receptor, mainly studied in the central nervous system, has not been 144 characterized in the liver or hepatocyte. In order to determine its real involvement in HCV 145 infection as a target of SB258585, we quantified its expression level in the liver. To do so, we 146 compared its distribution by qRT-PCR in seventeen different human tissues. This analysis 147 showed that 5-HT6 was highly expressed in brain tissues and intestine ( Fig. 2C ). It was also 148 expressed in testis, while it was not detected in all the other tissues, including the liver ( Fig.  149 2C). Quantification of 5-HT6 mRNA in Huh-7 cells by qRT-PCR showed a DCt of around 18 150 as compared to the housekeeping gene RPLP0, confirming an almost complete absence of 151 detection of 5-HT6 in this hepatic cell line. Not surprisingly, we were unable to detect the 5-152 HT6 protein by western blot and flow cytometry by using different antibodies (data not 153 shown). This observation implies that the effect observed on HCV infection is probably not 154 connected to 5-HT6. 155 5-HT6 is a G-protein coupled receptor (GPCR), associated with a G alpha stimulatory protein 156 (Gas). This Gas activates the adenylyl cyclase to produce cAMP, which in turn activates 157 protein kinase A (PKA) (18). However, GPCR agonists and antagonists often show affinity 158 for additional GPCR than the one specifically targeted. Therefore, we evaluated whether the 159 presence of 5-HT6 antagonist leads to a regulation of the PKA pathway, likely through 160 modulation of other GPCRs. We thus performed a western blot with an antibody specific for 161 PKA phosphorylated substrates. The cell permeable inhibitor of cAMP-dependent protein 162 kinase (PKA) H89 was used as a positive control. This compound is described to inhibit PKA 163 by competitive binding to the ATP site on PKA catalytic subunit (19) . As shown in Fig. 2D , 164 SB258585 reduced the phosphorylation level of PKA substrates in a similar manner as the 165
PKA inhibitor H89. 166
Therefore, our observations about the phosphorylation level of PKA substrates suggest 167 that the off-target effect of SB258585 targets a factor involved in PKA activation, likely 168
another GPCR coupled to a Gas protein. According to the kinetics shown in Fig. 2A , SB258585 seems to inhibit HCV entry. 173
The inhibitory effect of SB258585 on HCV entry was then validated with the help of 174 retroviral pseudo-particles harboring HCV envelope glycoproteins (HCVpp) from JFH1strain 175 (genotype 2a) ( Fig. 3A) . SB258585 had no effect on adenovirus infection, indicating that this 176 compound has not a global effect on viral entry ( Fig. 3B ). We also confirmed its inhibitory 177 effect on primary human hepatocytes (PHHs) infected by HCV strain JFH1 (genotype 2a) 178 In order to better understand the mechanism of action of SB258585 as an inhibitor of 182 HCV infection, we decided to test another characterized 5-HT6 antagonist, SB399885 which 183 shares a very similar structure (Fig. 3F ). The fact that both antagonists inhibit a common step 184 of HCV infection ( Fig. 2A , 3G-H) in the absence of their main targeted receptor, modulating 185 PKA activity ( Fig.2D ) suggests that their common structure of 186 piperazinylbenzenesulfonamides is likely responsible for a common off-target effect. 187
To better identify the entry step targeted by these compounds, we performed a time-188 of-addition assay, using proteinase K and bafilomycin A respectively as controls of early and 189 late step of viral entry. Proteinase K blocks viral internalization through proteolysis of viral 190 particles exposed to the extracellular compartment, while Bafilomycin A blocks the 191 endosomal acidification resulting in the inhibition of viral fusion (28). A comparison of 192 SB258585 and SB399885 to the kinetics of proteinase K and Bafilomycin A treatment rather 193 revealed an inhibition of a late step of the entry process ( Fig. 3E, 3I ). It is worth noting that 194 the slight difference in the SB258585 curves obtained at 20µM and 100 µM was not 195 statistically significant. 196 Knowing that CD81-CLDN1 interaction is necessary for clathrin-dependent 197 endocytosis of HCV particles (8), we analyzed the effect of these 198 piperazinylbenzenesulfonamides on CD81-CLDN1 co-localization. A dose-dependent 199 decrease of CD81-CLDN1 co-localization was observed after treatment with SB258585, as 200 confirmed by determining the Pearson correlation coefficient ( Fig. 4A-B ). Furthermore, we 201 observed a decrease of cell surface CLDN1 expression by flow cytometry analyses in non-202 infected ( Fig. 4C ) and infected cells (data not shown) treated with SB258585. This could 203 explain the alteration in CD81-CLDN1 co-localization. The same phenotype was also 204 observed in cells treated with SB399885 ( Fig. 4D ). Furthermore, kinetic analyses revealed 205 that the decrease of CLDN1 cell surface expression after SB258585 treatment is quite rapid 206 and reversible ( Fig. 4E-F ). It is worth noting that this compound had no effect on the 207 distribution of other major HCV entry co-receptors, including CD81 ( Fig. 5 ). 208 209
Alteration of cell surface expression of CLDN1 mediated by SB258585 is due to CLDN1 210 intracellular accumulation. 211
Decreased CLDN1 cell surface expression could be due either to CLDN1 degradation 212 or intracellular accumulation. To answer this question, we first analyzed the total level of 213 CLDN1 by western blot. Treatment of Huh-7 cells with SB258585 and SB399885 did not 214 affect the amount of CLDN1 ( Fig. 4G ), indicating that these compounds do not induce 215 CLDN1 degradation. Instead, immunofluorescence analyses showed an intracellular 216 accumulation of CLDN1 in the presence of SB258585 ( Fig. 4H ), confirmed by an increased 217 co-localization with the intracellular markers TGN46 (Fig.4I ), ERGIC53 and GM130 (data 218 not shown). This intracellular accumulation could be due either to an increase in CLDN1 219 endocytosis or to an alteration in CLDN1 export. To elucidate this, we used an internalization 220 assay based on cell surface biotinylation to determine the kinetics of CLDN1 endocytosis in 221 the presence or absence of the drug. As shown in Fig. 4J , CLDN1 endocytosis was maximal 222 after 1h. The protein amount was comparable in DMSO or SB258585 treated cells, suggesting 223 no alteration of CLDN1 endocytosis. Conversely, at later time points, biotinylated CLDN1 224 disappeared in DMSO treated cells, suggesting that it had either been degraded or recycled to 225 the cell surface, while it remained stored intracellularly in the presence of the compound. This 226 is in agreement with the accumulation of CLDN1 detected by immunofluorescence ( Fig. 4H) . 227
Since no change in total CLDN1 level was observed between DMSO and SB258585 228 treatment ( Fig. 4G) , it is unlikely that endocytosed CLDN1 is degraded. Rather, CLDN1 must 229 be recycled to the plasma membrane. Accumulation of intracellular CLDN1 observed after 230 SB258585 treatment ( Fig. 4H -J) suggests a defect of CLDN1 recycling and explains the 231 decrease of CLDN1 at the cell surface. 232
233

PKA inhibition affects HCV late entry step and regulates CLDN1 trafficking. 234
To further confirm whether SB258585 inhibitory effect on HCV could be mediated by 235 the PKA downstream pathway, we tested the effect of PKA inhibitor H89 on HCV infection. 236
As reported by Farquhar and co-workers (29), we confirmed a dose-dependent inhibitory 237 effect of this compound on both HCVpp and HCVcc of JFH1strain (genotype 2a) at non-toxic 238 concentrations ( Fig. 6A-C) . We then used a time-of-addition assay with increasing 239 concentrations of H89, and our data indicated an inhibitory effect at a late step of HCV entry 240 ( Fig. 6D ). Furthermore, as observed for the two piperazinylbenzenesulfonamides, H89 241 treatment also induced a decrease of cell surface expression of CLDN1 ( Fig. 6E ) without 242 affecting its total level of expression ( Fig. 4G ), but rather resulting in its intracellular 243 accumulation ( Fig. 4H-I ). In addition, transfection of an exogenous catalytic subunit of PKA 244 (PRKACA) followed by stimulation of PKA with the activator of adenylyl cyclase forskolin, 245 also increased the phosphorylation level of PKA substrates (Fig. 7A ). Interestingly, PKA 246 stimulation caused an increase in cell surface expression of CLDN1 but no increase in 247 CLDN1-CD81 co-localization ( Fig. 7B -C). In agreement with this data, no increase in HCV 248 infection was observed after activation of PKA ( Fig. 7D ). 249
Similar experiments were performed activating the PKA pathway by overexpression 250 of a GPCR, through exogenous transfection of a plasmid encoding 5-HT6 in Huh-7 cells. The 251 increased phosphorylation level of PKA substrates (Fig. 7E) , suggested that the exogenous 252 receptor is functional and able to activate the PKA downstream pathway. As observed after 253 PKA transfection, overexpression of 5-HT6 led to an increase in CLDN1 cell surface 254 expression ( Fig. 7F ), also observed upon SB258585 treatment ( Fig. 7G ). However, this 255 increase in CLDN1 cell surface localization did not correlate with an increase in CLDN1-256 CD81 co-localization ( Fig. 7H ) or HCV infectivity ( Fig. 7I) . 257
Together, these data strongly suggest that PKA regulates CLDN1 localization at the 258 cell surface. However, its activation does not seem to be sufficient to mediate CLDN1 259 interaction with CD81, which is necessary for HCV entry. Similarly, an increase of CLDN1 260 cell surface expression without modification of CLDN1-CD81 interaction and HCV infection 261 was observed after over-expression of CLDN1 ( Fig. 7J -L). The failure in enhancing HCV 262 infection upon CLDN1 overexpression is in accordance with previous data (5). Together, 263 these results suggest that decreasing CLDN1 at plasma membrane strongly impacts HCV 264 entry, while increasing CLDN1 alone has no effect, probably due to a lack of recruitment to 265 its main partner CD81. 266
One potential explanation for the failure in increasing CLDN1-CD81 co-localization 267 could be a limited availability of endogenous CD81. To address this hypothesis, we 268 overexpressed this tetraspanin concomitantly with the GPCR 5-HT6. However, no 269 enhancement of HCV infection was observed ( Fig. 8A ), suggesting that increasing the 270 available quantity of both co-receptors was not sufficient to enhance their interaction and 271 consequently viral entry. 272 EGFR signaling has been described as important for CLDN1-CD81 interaction (30, 273 31) . To verify if our phenotype was due to an insufficient activation of this receptor and its 274 downstream pathway, we treated Huh-7 with EGF. Although the stimulation induced the 275 phosphorylation of EGFR and thus its activation ( Fig. 8B ), no enhancement of infectivity, but 276 rather a slight decrease, was observed in our hands after increase of cell surface CLDN1 277 induced by transfection of 5-HT6 GPCR (Fig. 8C ). Therefore, an additional signal upstream 278 of EGFR is likely necessary to relocalize CLDN1 to the site of interaction with CD81. 279 280
The C-terminal region of CLDN1 is not involved in PKA-mediated inhibition. 281
Predicted phosphorylation sites in the cytosolic domains of CLDN1 are only present in 282 the C-terminal region of CLDN1 (32) and could be responsible for its localization. A mutant 283
where the cytosolic C-terminus of CLDN1 was deleted has previously been described to 284 remain functional for HCV entry (5). We therefore used this mutant to determine whether the 285 effect of 5-HT6 activation antagonists is maintained when CLDN1 C-terminus region is 286 deleted. For this, we generated a CRISPR/Cas9 CLDN1 KO cell line ( Fig. 9A-B ), and we re-287 expressed a wild type or a C-terminal deleted CLDN1 (ΔCter) in this cell line ( Fig. 9C-D) . 288
After verification that the transfection level and the surface localization of the two constructs 289 were comparable ( Fig. 9C) , we infected the cells with HCV in the presence or absence of 290 SB258585. As shown in Fig. 9D , the absence of the C-terminus of CLDN1 did not alter the 291 sensitivity of HCV infection to SB258585 or H89, suggesting that CLDN1 C-terminal 292 cytosolic tail is not a direct target for PKA activity and is not required for its recycling. HCV entry is a highly complex multi-step process involving a series of cellular 296 proteins. Trafficking of these entry factors provides an additional level of complexity in the 297 regulation of HCV entry. Here, by screening a chemical compound library, we identified the 298 antagonist of 5-HT6 SB258585 as a novel inhibitor of HCV entry process. This drug, as well 299 as another 5-HT6 antagonist SB399885, with which it shares similarities in structure, inhibits 300 a post-binding step of HCV entry in a 5-HT6 independent manner. These two drugs induced a 301 decrease in recycling of HCV entry co-receptor CLDN1 and its co-localization with CD81. 302
The resulting reduction of CLDN1-CD81 interaction, known to be critical for HCV 303 internalization, likely explains the drop of HCV infectivity. Treatment with these drugs 304 showed a reduction in PKA activity and the involvement of this kinase-related pathway was 305 confirmed to regulate CLDN1 localization and HCV late entry step. 306
The attempt to detect 5-HT6 in liver biopsies and hepatocytes was unsuccessful. This 307 failure in detecting 5-HT6 mRNA is supported by other reports (33). In addition, SB258585 308 and SB399885 are supposed to inhibit 5-HT6 in a highly specific way at nanomolar 309 concentrations. Therefore, the fact that in our hands the inhibition is only observed at 310 micromolar concentrations supports the idea of an effect on another target, for which the drug 311 shows less affinity. However, although the major target of these drugs in our model is 312
unlikely to be 5-HT6, these chemical compounds inhibit PKA activity, suggesting an 313 inhibitory effect on one or several other GPCRs likely associated to a Ga stimulatory protein. 314
According to Stitch 5.0 prediction (17), SB258585 shows an affinity for other 5-HT receptors, 315
including the GPCR coupled to Gas 5-HT7, recently shown to play a role in liver fibrosis 316 (33). Unfortunately no data are available concerning SB399885, although the common 317 structure could suggest similar low-affinity targets. 318 PKA likely controls the export of CLDN1. Indeed, a down-regulation of PKA activity 319 reduces the cell surface expression of CLDN1, whereas its activation shows a direct increase 320 of this tight junction protein at cell surface, confirming a direct correlation between PKA 321 pathway and CLDN1 subcellular localization. The 5-HT6 receptor is a GPCR associated with 322 a G alpha stimulatory protein, known to activate the PKA pathway (34). Therefore, it is not 323 surprising that its overexpression stimulates PKA signaling and the export of the tight 324 junction protein CLDN1, similarly to what happens upon direct PKA transfection or 325 activation. Therefore, this experiment reinforces the hypothesis of a role for GPCRs in 326 regulating PKA signaling in hepatocytes. This is in line with a previous report showing that 327 PKA inhibitors affect HCV entry (29) . 328
Activation of the PKA pathway either by forskolin treatment, or by overexpression of 329 the exogenous GPCR 5-HT6, or by overexpression of PKA catalytic subunit itself, increased 330 CLDN1 export at the surface or rescued its surface localization in cells treated with 331 SB258585. However, this was not sufficient to increase the basal level or to rescue HCV 332 infection. Similarly, over-expression of CLDN1 led to an increase in CLDN1 expression at 333 the cell surface without increasing HCV entry. In our case, in addition to analyzing CLDN1 334 expression at the cell surface and HCV infection, we also monitored CD81-CLDN1 co-335 localization, which was not rescued despite re-export of CLDN1 at the cell surface. Thus, 336 there seems to be a disconnect between the level of CLDN1 expressed at the cell surface and 337 CD81-CLDN1 interaction. These observations are in accordance with Farquhar's work (29), 338
where treatment with forskolin did not enhance HCVcc entry. Since CLDN1 interaction with 339 the tetraspanin CD81 is necessary to mediate HCV endocytosis (6, 7), this could explain the 340 lack of rescue of HCV infection. The reason why CLDN1-CD81 co-localization is not 341 restored upon PKA activation remains unclear. One possibility could be that in rescue 342 experiments, despite the restoration of cell-surface expression of CLDN1, CD81 is no longer 343 available to interact with CLDN1. The interaction between these two proteins is described to 344 be regulated by the EGF receptor through HRas signaling (30, 31). However, neither 345 overexpression of CD81 concomitantly with the GPCR 5-HT6, nor EGF stimulation restored 346 the phenotype. This suggests that an additional signal upstream of EGFR is needed to target 347 CLDN1 to the site of interaction with CD81. Further investigations are therefore required to 348 better characterize the nature and the dynamics of the interaction between CLDN1 and CD81. 349
However, we cannot exclude that this defect in HCV late entry step is not only due to the 350 decreased interaction between CLDN1 and CD81. In addition to its involvement during 351 exocytosis, there are in fact evidences of a role for cAMP/PKA pathway during endocytosis 352 (reviewed in (35)). Therefore, the defect in HCV entry could not only be associated to 353 CLDN1 localization change, but also to a general perturbation of the membrane trafficking, 354 directly impacting HCV endocytosis. Further investigations are needed in order to elucidate 355 the mechanism connecting PKA pathway activation and endocytosis, necessary to better 356 clarify its additional involvement in HCV entry. 357
Regulation of CLDN1 trafficking in hepatocytes remains poorly characterized. 358
However, the CLDN1 C-terminal cytosolic tail presents several potential sites of post-359 translational modification, including phosphorylation and ubiquitination, which could 360 potentially play a role in its trafficking (36). Indeed, other reports indicate a role for the 361 phosphorylation of CLDN1 cytosolic tail in the regulation of its subcellular localization in 362 non-hepatic cells (37-39), or through a competition between phosphorylation and 363 ubiquitination (40), as described for other members of the CLDN family (41, 42). However, 364 in our experimental work, the absence of the C-terminus of CLDN1 did not alter the 365 sensitivity of HCV infection to 5-HT6 and PKA antagonists, excluding a role for a direct 366 phosphorylation on CLDN1. Therefore, an additional, as of yet unidentified, intermediate 367 protein likely phosphorylated by PKA is probably involved in regulation of CLDN1 368 localization in the hepatocyte. However, cAMP/PKA pathway activation has been shown to 369 stimulate exocytosis of several proteins towards both apical and basolateral surface in 370 hepatocytes (reviewed in (35)), suggesting a conserved mechanism of export. 371
Several compounds targeting other GPCRs were identified as HCV inhibitors in our 372 screen. Previous studies described antihistamines, neuroleptic drugs and other ligands of 373
GPCRs as inhibitors of HCV entry (16, 43, 44) . In the future it would be interesting to test if 374 the viral resistance mutations against any of these drugs eventually confer cross-resistance to HCS screens (50, 51). This suggests that a possible common mechanism, potentially affected 384 by drugs targeting 5-HT receptor, might be used by different viruses. In this context, CLDN1 385 might not be the only protein whose trafficking is altered by modulation of 5-HT pathway. 386
Interestingly, in immune cells treated with an inhibitor of 5-HT uptake, HIV entry receptor 387 and co-receptor were also observed to be down-regulated at the cell surface (52); however, 388 the mechanism was not investigated. Further studies are necessary in order to better clarify if 389 there is actually a common pathway influencing the entry of all these viruses that could 390 represent a potential drug target for wide-range antiviral development. 391
In summary, we identified SB258585 and SB399885, antagonists of 5-HT6 receptor, 392 as inhibitors of a post-binding step of HCV entry. Although we confirmed the absence of 5-393 HT6 in liver and hepatic cells, we proved an inhibition of PKA activity as a consequence of 394 the treatment, suggesting an off-target effect of these drugs on another GPCR. We thus 395 confirmed an involvement of PKA in a post-binding step of HCV entry, showing that 396 modulation of PKA activity regulates CLDN1 localization, through regulation of CLDN1 397 recycling towards the cell surface. We thus suggest a role for PKA in the liver, as a regulator 398 of CLDN1 export, which affects the HCV entry process influencing viruses of the six major 399 genotypes. Finally, our work reinforces the hypothesis of a common pathway shared by 400 several enveloped viruses, involving PKA-dependent signaling in late steps of viral entry. 401
MATERIAL AND METHODS 402
Cell culture. Huh-7 and Huh-7.5 cells have been previously described (53, 54) and were 403 cultured at 37°C with 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) 404 supplemented with 10% fetal bovine serum (FBS). Experiments were performed in DMEM 405 supplemented with 5% FBS. Huh-7 and Huh-7.5 cells were authenticated by the company 406
Multiplexion, performing a Multiplex human cell line Authentication Test (MCA) as 407 described at www.multiplexion.de. 408
For experiments using forskolin and EGF, cells were preincubated during 2h in serum-free 409 medium before incubation with the compound. DMEM, Opti-MEM, phosphate-buffered 410 saline (PBS), goat serum, and FBS were purchased from Life Technologies. PHH were 411 purchased from Biopredic and cultured at 37°C in supplemented Hepatocyte Basal Medium 412 (Clonetics™ HCM™ BulletKit™, Lonza). 413
Viruses. Cell culture derived HCV (HCVcc) were produced by electroporation of Huh-7 cells 414 with in vitro transcribed RNA of a modified JFH1 plasmid kindly provided by T. Wakita 415 (National Institute of Infectious Diseases, Tokyo, Japan) (11). This modified JFH1 bears 416 some titer-enhancing mutations and the reconstitution of the A4 epitope in E1 (10). Sequence-417 confirmed virus stocks of JFH1-based Core-NS2 HCV recombinants were previously 418 generated as described (21) (22) (23) (24) (25) (26) (27) . 419
Antibodies. Anti-HCV E1 mouse monoclonal antibody (MAb) A4 was produced in vitro 420 using a MiniPerm apparatus (Heraeus) following the manufacturer's protocol. Anti-CD81 421 MAb (5A6) was kindly provided by S. Levy (Stanford University). Anti-SRB1 antibody 422 C1671 was kindly given by A. Nicosia (OKAIROS, Italy). Anti-CLDN1 (OM 8A9-A3) MAb 423 has been previously described (55). Anti Phospho-(Ser/Thr) PKA Substrate (9621) Cells were then permeabilized with 0.1% Triton X-100 in PBS for 3 minutes at room 480 temperature and HCV infected cells were revealed by immunofluorescence with anti-E1 481 antibody (MAb) A4 (1:1000 dilution) for 30 minutes at room temperature. Goat anti-mouse 482
Alexa-488 was used as a secondary antibody (1:500 dilution), while nuclei were labeled with 483 DAPI (1:500 dilution) for 30 minutes at room temperature. Two fields per well were acquired 484 using the 20X objective (NA 0.45) using excitation laser (Ex) at 405 nm and emission filter 485 Compounds reducing the cell number by more than 35% compared to the average of DMSO 490 control wells were considered toxic and discarded. Compounds decreasing the percentage of 491 infection of at least 45%, whose effect was confirmed upon re-infection, were identified as 492 positive hits. Image analysis parameters of Columbus software are available upon request. 493 JFH1 infection assay. JFH1-HCVcc infection was quantified as previously described (10). 494
Core-NS2 HCV recombinant infection assay. Huh7.5 cells were plated at 7000 cells/well in 495 PDL coated 96 well plates. The following day, four replicates of the described Core-NS2 496 HCV recombinants were mixed with different concentrations of SB258585 in DMEM 497 supplemented with 10% FBS, along with 8 replicates of virus only without SB258585, and 498 added to Huh7.5 cells for 3 h. Following this incubation, the cells were washed and full 499 medium was added. After a total of 48 h post virus inoculation, the numbers of focus forming 500 units were visualized by HCV-specific immunostaining using NS5A antibody, 9E10 (24). 501
Counting was automated using an ImmunoSpot Series 5 UV Analyzer as described (57) HCVpp and infection assays. HCVpp bearing E1E2 glycoproteins of strain JFH1 (genotype 508 2a) were produced as previously described (58). RD114pp were produced using a plasmid 509 encoding the feline endogenous virus RD114 glycoprotein (59). Huh-7 cells were incubated 510 with pseudotyped particles for 3h at 37°C, concomitantly with increasing concentrations of 511 drugs. At 48h post-infection, firefly luciferase (FLuc) assays were performed following the 512 manufacturer's protocol (Promega). 513 HCVcc entry assay. After 2 h of JFH1-HCVcc attachment at 4°C, Huh-7 cells were washed 514 and shifted to 37°C to induce viral internalization. Each drug was added every 15 minutes 515 during a 2 h kinetic. Proteinase K (50 µg/ml) and bafilomycin A (25 nM) were included as 516 controls respectively for an early and a late step of viral entry. When treated with proteinase 517 K, cells were washed in cold PBS and incubated with proteinase K for 1 h at 4°C under gentle 518 agitation, before washing them again and adding fresh medium at 37°C. The infection rate 519 was calculated by IF 30 h later and each time point was normalized to the corresponding 520 DMSO condition. 521
Adenovirus infection. A recombinant adenovirus (AdV) expressing a green fluorescent 522
protein was generated as previously described (10). Huh-7 cells were inoculated with the 523 virus for 2 h at 37°C concomitantly with increasing concentration of SB258585 and cultured 524
for 24 h at 37°C. AdV infections were scored using an Axioplan2 epifluorescence microscope 525 (Zeiss) after fixation and nuclei staining with Hoechst. 526 Viability assay. Huh-7 cells were incubated for 2 h with increasing concentrations of the 527 indicated compound. A MTS assay was performed 28 h post-treatment, according to the 528 manufacturer's protocol (Promega) in order to evaluate cell viability. 529
Immunofluorescence and quantification of CLDN1 co-localization with markers of 530 subcellular compartments. Huh-7 cells previously seeded on coverslips were treated with 531 the indicated compounds. After treatment cells were fixed for 30 minutes with 3 % 532 paraformaldehyde. Cells were permeabilized during 5 minutes with 0.1 % Triton X-100 and 533 saturated for 30 minutes with PBS containing 10 % goat serum. Primary antibodies were 534 incubated during 30 minutes in PBS-goat serum. After three washes, secondary antibodies 535 and DAPI were added during 30 minutes. After three more washes, coverslips were mounted 536 on glass slides using Mowiol. Images were taken using a Zeiss-LSM880 or a Zeiss-LSM780 537 confocal microscope, with a 63X oil objective. Pearson correlation coefficients were 538 calculated using the Fiji coloc2 plugin on regions of interest (ROIs) from single cells, 539 designed on the basis of cell compartment labeling. Each experiment was repeated at least 540 three times and at least 40 cells for each condition were quantified. 541
Quantification of CD81-CLDN1 colocalization. Huh-7 cells were seeded on coverslips and 542 treated with the indicated inhibitor. After treatment cells were fixed for 30 minutes with 3 % 543 paraformaldehyde. Cells were incubated for 30 minutes with PBS containing 10 % goat 544 serum. Primary antibodies diluted in PBS-goat serum were added during 30 minutes. After 545 three washes, secondary antibodies and Hoechst were added for another 30 minutes. After 546 three more washes, coverslips were mounted on glass slides using Mowiol. Images were 547 taken using a Zeiss-LSM880 confocal microscope, with a 63X oil objective. Pearson 548 correlation coefficients were calculated using the Fiji coloc2 plugin on regions of interest 549 (ROIs) from single cells, designed on the bases of CD81 surface labeling. Each experiment 550 was repeated at least three times and a total of at least 40 cells for each condition were 551 quantified. 552
Flow cytometry. Huh-7 cells treated with the indicated compound for the indicated period of 553 time or siRNA transfected Huh-7 cells were incubated for 30 minutes at 4°C with the 554 indicated primary antibody diluted in cold PBS supplemented with 2 % BSA. After three 555 washes with cold PBS-BSA, cells were incubated for 30 minutes at 4°C with secondary 556 antibodies. After three more washes, cells were incubated for another 30 minutes with cold 557 PBS supplemented with 2 mM EDTA and then resuspended and fixed with a formalin 558 solution at a final concentration of 1.5 % formalin. For PKA-HA labeling, cells were 559 permeabilized for 30 minutes with 5% saponin and each following step was performed in the 560 presence of 5% saponin. Cells were analyzed using a BD FACSCANTO II Flow Cytometer. 561
Analyses were performed using Weasel and FlowJo softwares. 562 Surface biotinylation and endocytosis. Biotinylation assay was performed as previously 563 described (60). A western blot was performed in order to detect CLDN1. Proteins were 564 resolved by SDS-PAGE and transferred on a nitrocellulose membrane. The membrane was 565 immunoblotted with the indicated primary antibody, followed by peroxidase-coupled 566 secondary antibodies. Proteins were detected using a LAS3000 machine (Fuji). 567 cDNA transfection. Huh-7 cells were seeded in 24-well plates and transfected with 250 ng of 568 DNA using TransIT®-LT1 Transfection Reagent, according to the manufacturer's protocol. We thank F.L. Cosset, C. Rice and T. Wakita for providing essential reagents. We also thank 601 S. Ung for his help in preparing the Fig.s and L. Linna for manuscript proofreading. We are 602 very grateful to A. Danneels for her precious help during the revisions. Immunofluorescence 603 and flow cytometry analyses were performed with the help of the imaging core facility of the 604
BioImaging Center Lille Nord-de-France. 
